IMRT Cuts Prostate Cancer Costs 40%
In 2022, Huntsman treated more than 1,200 early-stage prostate cancer patients with IMRT, demonstrating a clear cost advantage over proton therapy. IMRT reduces the overall expense of radiation treatment for prostate cancer compared with proton therapy, while maintaining excellent clinical results. Medical Disclaimer: This article is for informational purposes